Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignant Neoplasm of the Cervical Esophagus”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Early research (Phase 1)Ended earlyNCT00094978
What this trial is testing

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

Who this might be right for
Carcinoma, Small CellCarcinoma, Non-Small-Cell LungEsophageal Neoplasms+1 more
National Cancer Institute (NCI) 23
Early research (Phase 1)Ended earlyNCT05861947
What this trial is testing

Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

Who this might be right for
RelapseAdvanced Malignant NeoplasmNon Small Cell Lung Cancer+5 more
Aurigene Discovery Technologies Limited 21
Not applicableEnded earlyNCT01366833
What this trial is testing

Optimal Management of Malignant Dysphagia

Who this might be right for
Malignant DysphagiaEsophageal Cancer
McGill University Health Centre/Research Institute of the McGill University Health Centre 3
Not applicableStudy completedNCT00900302
What this trial is testing

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Who this might be right for
Cancer
OHSU Knight Cancer Institute 98
Testing effectiveness (Phase 2)Study completedNCT02830594
What this trial is testing

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

Who this might be right for
Gastric AdenocarcinomaGastric Squamous Cell CarcinomaGastroesophageal Junction Adenocarcinoma+3 more
City of Hope Medical Center 14
Early research (Phase 1)Looking for participantsNCT06043466
What this trial is testing

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Who this might be right for
Colorectal CancerEsophagus CancerGastric Cancer+4 more
Chongqing Precision Biotech Co., Ltd 30
Not applicableWithdrawnNCT00372450
What this trial is testing

Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal CancerGastrointestinal Complications
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Study completedNCT02389751
What this trial is testing

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

Who this might be right for
Gastroesophageal Junction AdenocarcinomaMalignant Neoplasm of the Cervical EsophagusMalignant Neoplasm of the Thoracic Esophagus+5 more
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT03777813
What this trial is testing

Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer

Who this might be right for
Esophagus CancerUnresectable Malignant Neoplasm
UNICANCER 112
Not applicableLooking for participantsNCT00242723
What this trial is testing

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Who this might be right for
Thoracic CancersMalignant Pleural Mesotheliomas NOSLung Cancer NOS+3 more
National Cancer Institute (NCI) 1,559
Not applicableStudy completedNCT03301493
What this trial is testing

Genomic Testing and Resulting Medical Decisions

Who this might be right for
Cancer of Unknown OriginCancer RefractoryCancer of Stomach+12 more
Arbeitsgemeinschaft medikamentoese Tumortherapie 1,500